– Company to receive funding for novel therapies targeting Delta F508, most common CF mutation – Cambridge, Mass., May 7, 2012 — Proteostasis Therapeutics, Inc. (PTI), a company developing novel therapeutics that regulate protein homeostasis to improve outcomes for patients with neurodegenerative
